New Drug Approved for Chronic Lymphocytic Leukemia — Physician’s First Watch
New Drug Approved for Chronic Lymphocytic Leukemia
By Kristin J. Kelley
The FDA has granted accelerated approval of ibrutinib (marketed as Imbruvica) for patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Approval for the drug — which blocks the enzyme needed for cancer growth (Bruton's tyrosine kinase) — was based on a clinical trial of 48 CLL patients who, on average, were treated with four previous therapies. All participants received ibrutinib, and the cancer responded in almost 58%.
Ibrutinib was approved to treat mantle cell lymphoma in November 2013.